Sectra收购Oxipit，提升诊断影像中的自主AI能力-动脉网

Sectra acquires Oxipit, advancing autonomous AI capabilities in diagnostic imaging

CISION 等信源发布 2026-03-05 16:03



可切换为仅中文







LINKÖPING, Sweden

林雪平，瑞典

，

March 5, 2026

2026年3月5日

/PRNewswire/ --

International medical imaging IT and cybersecurity company

国际医疗影像IT与网络安全公司

Sectra

赛克特拉

(STO: SECT B)

（STO：B部分）

has entered into an agreement to acquire Oxipit, UAB, a Lithuanian company specializing in AI-based solutions for radiology. Oxipit holds the first CE Class IIB certification for autonomous AI in chest X-ray analysis. The transaction is subject to customary closing conditions and is expected to be completed during March 2026..

已达成协议收购立陶宛公司Oxipit, UAB，该公司专注于基于人工智能的放射学解决方案。Oxipit拥有首个用于胸部X光分析的CE Class IIB认证的自主人工智能。该交易需符合惯例的交割条件，预计将于2026年3月完成。

Most AI in radiology today acts as decision support, flagging findings, suggesting measurements, or assisting prioritization. These tools support radiologists but do not replace any part of the reporting process. Autonomous AI represents a different model. It is developed and validated to independently complete a specific diagnostic task under controlled clinical conditions.

当今放射学中的大多数人工智能充当决策支持角色，标记结果、建议测量或协助优先级排序。这些工具为放射科医生提供支持，但并未取代报告过程的任何部分。自主人工智能则代表了一种不同的模式。它被开发和验证为在受控临床条件下独立完成特定诊断任务。

The scope of autonomy is clearly defined, performance thresholds are rigorously validated, and use is governed by regulatory approval..

自主性的范围有明确的定义，性能阈值经过严格的验证，并且使用受到监管批准的约束。

Oxipit's ChestLink is a leading example of this autonomous approach. Within its defined clinical scope, it is designed to automatically identify and clear high-confidence normal chest X-ray examinations from the radiologist's worklist. This allows radiologists to focus their expertise on cases with a higher probability of disease.

Oxipit的ChestLink是这种自主方法的领先示例。在其定义的临床范围内，它旨在自动识别并将高可信度的正常胸部X光检查从放射科医生的工作列表中移除。这使得放射科医生能够将专业知识集中在疾病概率更高的病例上。

By safely reducing routine workload, this model directly addresses the growing challenge of rising imaging volumes and persistent workforce constraints, while operating under rigorously validated safety thresholds. ChestLink holds CE Class IIb certification*, reflecting the elevated regulatory and clinical validation standards required for autonomous AI applications in healthcare..

通过安全地减少常规工作量，该模型直接应对了日益增长的影像量和持续的劳动力限制的挑战，同时在经过严格验证的安全阈值下运行。ChestLink 拥有 CE Class IIb 认证*，反映了自主人工智能应用于医疗保健所需的更高监管和临床验证标准。

ChestLink is already available through Sectra Amplifier Marketplace for AI, supporting seamless integration into existing radiology workflows.

ChestLink 已通过 Sectra Amplifier Marketplace for AI 提供，支持无缝集成到现有的放射学工作流程中。

'The ability to autonomously clear high-confidence normal cases mark a transformative step for radiology. By combining clinical confidence with intelligent automation, we can expand capacity, reduce radiologist workload, and generate substantial financial benefits through higher productivity and lower cost.

“自主清除高可信度正常病例的能力标志着放射学领域的变革性一步。通过将临床信心与智能自动化相结合，我们可以扩大容量、减轻放射科医生的工作量，并通过提高生产力和降低成本带来显著的经济效益。”

We look forward to continuing to sell Oxipit products in Europe and advancing the necessary regulatory approvals to bring it to more markets worldwide,' says Torbjörn Kronander, President and CEO of Sectra..

“我们期待继续在欧洲销售Oxipit产品，并推进必要的监管审批，将其引入全球更多市场，”Sectra总裁兼首席执行官托比约恩·克罗纳德表示。

Oxipit was founded in 2017 and has developed a portfolio of CE-marked AI solutions for radiology spanning chest X-ray, CT, and musculoskeletal imaging. The solutions are currently deployed across multiple markets internationally.

Oxipit 成立于2017年，已经开发了一系列带有CE标志的放射学人工智能解决方案，涵盖胸部X光、CT和肌肉骨骼成像。这些解决方案目前已在国际多个市场部署。

The Oxipit team will operate as a dedicated AI development center within Sectra's Imaging IT Solutions operating area. Alongside Sectra's own capabilities, Sectra's Amplifier service will remain an open, vendor-neutral ecosystem, providing healthcare providers access to AI applications from a wide range of vetted partners..

Oxipit团队将作为Sectra影像IT解决方案业务领域内的专用AI开发中心运营。除了Sectra自身的能力外，Sectra的Amplifier服务将继续作为一个开放的、供应商中立的生态系统，为医疗保健提供商提供来自众多经过验证的合作伙伴的AI应用程序访问权限。

The acquisition will be financed using Sectra's own funds and comprises an upfront cash consideration and an additional contingent consideration linked to commercial and regulatory milestones. Financial terms are not disclosed. The acquisition is not expected to have any material impact on the Sectra Group's sales and operating profit for the current year..

此次收购将使用Sectra的自有资金进行融资，包括一笔前期现金对价以及与商业和监管里程碑挂钩的额外或有对价。财务条款未披露。预计此次收购不会对Sectra集团本年度的销售和营业利润产生任何重大影响。

Answers to frequently asked questions about the acquisition are available on our website>>.

有关收购的常见问题解答，请访问我们的网站>>。

* CE class IIb certification confirms compliance with EU medical device regulations and permits commercialization within the EEA.

* CE IIb类认证确认符合欧盟医疗器械法规，并允许在欧洲经济区（EEA）内进行商业化。

Book a demo at ECR 2026

在ECR 2026预订演示

Visit Booth #D02 for a demonstration of Sectra's AI offering including the CE Class IIB-certified ChestLink solution. See how autonomous AI optimizes radiology workflows while maintaining high safety standards.

访问D02展位，观看Sectra的AI产品演示，包括获得CE Class IIB认证的ChestLink解决方案。了解自主AI如何在保持高安全标准的同时优化放射科工作流程。

Read more about our highlights at ECR and book your demo!

阅读更多关于我们在ECR的亮点，并预订您的演示！

For further information, please contact:

如需更多信息，请联系：

Dr. Torbjörn Kronander, CEO and President Sectra AB, 46 (0) 705 23 52 27

托比约恩·克罗纳德尔博士，Sectra AB公司首席执行官兼总裁，46 (0) 705 23 52 27

Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10

玛丽·埃克斯特罗姆·特拉加德， Sectra AB执行副总裁兼Sectra影像IT解决方案总裁，电话：46 (0)708 23 56 10

This information was brought to you by Cision

此信息由Cision提供给您

http://news.cision.com